Severe cerebral hypovolemia on perfusion CT and lower body weight are associated with parenchymal haemorrhage after thrombolysis.

about

Severe cerebral hypovolemia on perfusion CT and lower body weight are associated with parenchymal haemorrhage after thrombolysis.

Item

http://www.wikidata.org/entity/Q39061399

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@en

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@nl

type

Item

label

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@en

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@nl

prefLabel

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@en

Severe cerebral hypovolemia on ...... aemorrhage after thrombolysis.

@nl

P1476

Severe cerebral hypovolemia on ...... haemorrhage after thrombolysis

@en

P2093

A Eskandari

http://www.w3.org/2001/XMLSchema#string

B Jiang

http://www.w3.org/2001/XMLSchema#string

M Amiguet

http://www.w3.org/2001/XMLSchema#string

M Wintermark

http://www.w3.org/2001/XMLSchema#string

P Maeder

http://www.w3.org/2001/XMLSchema#string

P Michel

http://www.w3.org/2001/XMLSchema#string

R Meuli

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

Thrombolysis for acute ischaemic stroke

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)

Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Acute stroke imaging research roadmap.

Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set

Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator.

P2888

s00234-016-1775-x

P304

23-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00234-016-1775-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

S Tsetsou

P577

2016-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28028565

http://www.w3.org/2001/XMLSchema#string

P921

thrombolysis